Task force report on non-criteria manifestations: Thrombocytopenia

GabrielA Hernández-Molina, Xavier López-Karpovitch, Emilio Gonzalez, Antonio R. Cabral

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

Thrombotic manifestations, particularly when recurrent, are the antiphospholipid syndrome’s (APS) seal of identity. However, in a recent analysis comprising over 2,900 APS patients, the frequency of thrombocytopenia ranged from 30% to 46%. Accumulated data have also shown that between 10–15% of patients with immune thrombocytopenic purpura (ITP) may develop thrombosis depending upon their antiphospholipid antibody (aPL) profile. These statements could mean that these two apparent different settings are one and the same: “ITP” patients with positive aPL and patients with thrombocytopenia as their only APS clinical manifestation. What appears to define these “two” settings is the presence of aPL with lupus anticoagulant activity. Regardless of this evidence, according to the APS Classification criteria, an aPL-positive patient with thrombocytopenia but without a history of thrombosis or pregnancy morbidity is not classified as having APS. Herein, we provide relevant information regarding the pathogenic and clinical similarities and differences of platelet destruction seen in APS and ITP. Finally, we review the current therapeutic decisions in aPL-associated thrombocytopenia based on expert opinion and international consensus report for the management of ITP.

Original languageEnglish (US)
Title of host publicationAntiphospholipid Syndrome: Insights and Highlights from the 13Th International Congress on Antiphospholipid Antibodies
PublisherSpringer US
Pages195-206
Number of pages12
ISBN (Print)9781461431947, 9781461431930
DOIs
StatePublished - Jan 1 2012

Fingerprint

Antiphospholipid Syndrome
Advisory Committees
Antiphospholipid Antibodies
Thrombocytopenia
Idiopathic Thrombocytopenic Purpura
Thrombosis
Lupus Coagulation Inhibitor
Expert Testimony
Blood Platelets
Morbidity
Pregnancy

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Hernández-Molina, G., López-Karpovitch, X., Gonzalez, E., & Cabral, A. R. (2012). Task force report on non-criteria manifestations: Thrombocytopenia. In Antiphospholipid Syndrome: Insights and Highlights from the 13Th International Congress on Antiphospholipid Antibodies (pp. 195-206). Springer US. https://doi.org/10.1007/978-1-4614-3194-7_13

Task force report on non-criteria manifestations : Thrombocytopenia. / Hernández-Molina, GabrielA; López-Karpovitch, Xavier; Gonzalez, Emilio; Cabral, Antonio R.

Antiphospholipid Syndrome: Insights and Highlights from the 13Th International Congress on Antiphospholipid Antibodies. Springer US, 2012. p. 195-206.

Research output: Chapter in Book/Report/Conference proceedingChapter

Hernández-Molina, G, López-Karpovitch, X, Gonzalez, E & Cabral, AR 2012, Task force report on non-criteria manifestations: Thrombocytopenia. in Antiphospholipid Syndrome: Insights and Highlights from the 13Th International Congress on Antiphospholipid Antibodies. Springer US, pp. 195-206. https://doi.org/10.1007/978-1-4614-3194-7_13
Hernández-Molina G, López-Karpovitch X, Gonzalez E, Cabral AR. Task force report on non-criteria manifestations: Thrombocytopenia. In Antiphospholipid Syndrome: Insights and Highlights from the 13Th International Congress on Antiphospholipid Antibodies. Springer US. 2012. p. 195-206 https://doi.org/10.1007/978-1-4614-3194-7_13
Hernández-Molina, GabrielA ; López-Karpovitch, Xavier ; Gonzalez, Emilio ; Cabral, Antonio R. / Task force report on non-criteria manifestations : Thrombocytopenia. Antiphospholipid Syndrome: Insights and Highlights from the 13Th International Congress on Antiphospholipid Antibodies. Springer US, 2012. pp. 195-206
@inbook{f9bb5ee27a1647ba9a49a81de1e5676f,
title = "Task force report on non-criteria manifestations: Thrombocytopenia",
abstract = "Thrombotic manifestations, particularly when recurrent, are the antiphospholipid syndrome’s (APS) seal of identity. However, in a recent analysis comprising over 2,900 APS patients, the frequency of thrombocytopenia ranged from 30{\%} to 46{\%}. Accumulated data have also shown that between 10–15{\%} of patients with immune thrombocytopenic purpura (ITP) may develop thrombosis depending upon their antiphospholipid antibody (aPL) profile. These statements could mean that these two apparent different settings are one and the same: “ITP” patients with positive aPL and patients with thrombocytopenia as their only APS clinical manifestation. What appears to define these “two” settings is the presence of aPL with lupus anticoagulant activity. Regardless of this evidence, according to the APS Classification criteria, an aPL-positive patient with thrombocytopenia but without a history of thrombosis or pregnancy morbidity is not classified as having APS. Herein, we provide relevant information regarding the pathogenic and clinical similarities and differences of platelet destruction seen in APS and ITP. Finally, we review the current therapeutic decisions in aPL-associated thrombocytopenia based on expert opinion and international consensus report for the management of ITP.",
author = "GabrielA Hern{\'a}ndez-Molina and Xavier L{\'o}pez-Karpovitch and Emilio Gonzalez and Cabral, {Antonio R.}",
year = "2012",
month = "1",
day = "1",
doi = "10.1007/978-1-4614-3194-7_13",
language = "English (US)",
isbn = "9781461431947",
pages = "195--206",
booktitle = "Antiphospholipid Syndrome: Insights and Highlights from the 13Th International Congress on Antiphospholipid Antibodies",
publisher = "Springer US",

}

TY - CHAP

T1 - Task force report on non-criteria manifestations

T2 - Thrombocytopenia

AU - Hernández-Molina, GabrielA

AU - López-Karpovitch, Xavier

AU - Gonzalez, Emilio

AU - Cabral, Antonio R.

PY - 2012/1/1

Y1 - 2012/1/1

N2 - Thrombotic manifestations, particularly when recurrent, are the antiphospholipid syndrome’s (APS) seal of identity. However, in a recent analysis comprising over 2,900 APS patients, the frequency of thrombocytopenia ranged from 30% to 46%. Accumulated data have also shown that between 10–15% of patients with immune thrombocytopenic purpura (ITP) may develop thrombosis depending upon their antiphospholipid antibody (aPL) profile. These statements could mean that these two apparent different settings are one and the same: “ITP” patients with positive aPL and patients with thrombocytopenia as their only APS clinical manifestation. What appears to define these “two” settings is the presence of aPL with lupus anticoagulant activity. Regardless of this evidence, according to the APS Classification criteria, an aPL-positive patient with thrombocytopenia but without a history of thrombosis or pregnancy morbidity is not classified as having APS. Herein, we provide relevant information regarding the pathogenic and clinical similarities and differences of platelet destruction seen in APS and ITP. Finally, we review the current therapeutic decisions in aPL-associated thrombocytopenia based on expert opinion and international consensus report for the management of ITP.

AB - Thrombotic manifestations, particularly when recurrent, are the antiphospholipid syndrome’s (APS) seal of identity. However, in a recent analysis comprising over 2,900 APS patients, the frequency of thrombocytopenia ranged from 30% to 46%. Accumulated data have also shown that between 10–15% of patients with immune thrombocytopenic purpura (ITP) may develop thrombosis depending upon their antiphospholipid antibody (aPL) profile. These statements could mean that these two apparent different settings are one and the same: “ITP” patients with positive aPL and patients with thrombocytopenia as their only APS clinical manifestation. What appears to define these “two” settings is the presence of aPL with lupus anticoagulant activity. Regardless of this evidence, according to the APS Classification criteria, an aPL-positive patient with thrombocytopenia but without a history of thrombosis or pregnancy morbidity is not classified as having APS. Herein, we provide relevant information regarding the pathogenic and clinical similarities and differences of platelet destruction seen in APS and ITP. Finally, we review the current therapeutic decisions in aPL-associated thrombocytopenia based on expert opinion and international consensus report for the management of ITP.

UR - http://www.scopus.com/inward/record.url?scp=84949465682&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84949465682&partnerID=8YFLogxK

U2 - 10.1007/978-1-4614-3194-7_13

DO - 10.1007/978-1-4614-3194-7_13

M3 - Chapter

AN - SCOPUS:84949465682

SN - 9781461431947

SN - 9781461431930

SP - 195

EP - 206

BT - Antiphospholipid Syndrome: Insights and Highlights from the 13Th International Congress on Antiphospholipid Antibodies

PB - Springer US

ER -